| name | Implantable Contraceptives (e.g., Nexplanon) |
| classification | Hormonal Contraceptives - Progestin-only |
| pharmacokinetics | Progestin is slowly released from the implant over several years. Peak concentrations are achieved within several months of implantation, and serum levels gradually decline and become undetectable within a few months after removal. The exact pharmacokinetic profile will vary slightly based on the specific implant, but the overall effect is prolonged release of progestin, suppressing ovulation. |
| suggested dosage | A single implant is placed under the skin of the upper arm. Dosage is not in a traditional 'per dose' format. The method of administration is placement of the implant, which then delivers a continuous dose of hormone for up to 3 years. Consult with a healthcare provider for specifics. |
| indications | Contraception in a reliable, long-term manner. |
| safety in pregnancy | Pregnancy is not possible due to hormonal suppression of ovulation, although there may be very rare exceptions. A patient with a known pregnancy after implant insertion should seek immediate medical advice. |
| safety in breastfeeding | Limited data suggests these implants may have minimal impact on breast milk composition, and may not be contraindicated. However, this is a specific clinical question, and a healthcare provider should be consulted before use. |
| side effects | | 1 | Irregular bleeding (spotting, breakthrough bleeding, amenorrhea) | | 2 | Acne | | 3 | Mood changes | | 4 | Weight changes | | 5 | Headache | | 6 | Breast tenderness | | 7 | Nausea | | 8 | Decreased libido | | 9 | Pain or swelling at the implant site | | 10 | Infection at the implant site |
|
| alternatives | | 1 | | | 2 | | name | Condoms | | details | Barrier method of contraception. |
| | 3 | | name | Intrauterine devices (IUDs) | | details | Long-acting reversible contraceptives that work differently. |
| | 4 | | name | Diaphragms | | details | Barrier method of contraception. |
|
|
| contraindications | | 1 | Known hypersensitivity to progestins | | 2 | History of blood clots (thrombophlebitis or deep vein thrombosis) | | 3 | Severe liver disease | | 4 | Undiagnosed abnormal vaginal bleeding | | 5 | Breast cancer or other hormone-sensitive cancers (consider patient medical history) | | 6 | Severe cardiovascular disease |
|
| interactions | | 1 | | interaction | Some medications (e.g., certain anticonvulsants) may reduce the effectiveness of the implant. |
| | 2 | | interaction | Specific interactions depend on the concurrent medications, and should be discussed with a physician. |
|
|
| warnings and precautions | | 1 | Monitor for signs of blood clots (e.g., pain, swelling in the leg, chest pain). | | 2 | Regular follow-up with a healthcare provider is essential. | | 3 | Regular self-examination of the implant site for signs of infection. |
|
| additional informations | | 1 | | note | It is critical that the implant be placed and removed by a healthcare professional. Patients should be educated about what to expect and when to seek follow-up care. |
| | 2 | | note | The effectiveness of the implant is not affected by weight, for a healthy individual. |
| | 3 | | note | Implantable contraceptives are not for male use. This response is for informational purposes only and does not constitute medical advice. |
|
|
